Hexagon Bio’s diverse team combines computational biology and experimental investigation, with deep expertise at the intersection of these fields.
Maureen Hillenmeyer, PhD
CEO & Founder
Maureen is a founder and CEO of Hexagon Bio. Previously, she was director of the Genomes to Natural Products program and group leader at the Stanford Technology Genome Center.
Brian Naughton, PhD
Head of Data & Founder
Brian is a founder and head of data at Hexagon Bio. Previously, he was founding scientist at 23andMe.
Yi Tang, PhD
Founder
Yi is a founder of Hexagon Bio, Professor at UCLA, and a world expert on fungal enzymes and natural products.
Colin Harvey, PhD
Head of Biology & Chemistry & Founder
Colin is a founder and Head of Chemistry and Biology at Hexagon Bio. Previously, he led synthetic biology efforts for natural product discovery at the Stanford Genome Technology Center.
Andy Aymeloglu
Head of Engineering
Andy is the Head of Engineering at Hexagon Bio. Previously he was Director of Engineering at Palantir Technologies.
Tod Smeal, PhD
Chief Scientific Officer
Tod leads Hexagon Bio's drug discovery team. Previously, he was Chief Scientific Officer of Cancer Biology at Lilly Research Labs. Tod has led many oncology programs at Lilly, Pfizer, and SUGEN where he played key roles on lorlatinib, crizotinib, and nirogacestat.
→ Meet our team on LinkedIn.
David Goeddel, PhD
Managing Partner, The Column Group
Chairman, Hexagon Bio
Maureen Hillenmeyer, PhD
CEO & Founder, Hexagon Bio
Brian Naughton, PhD
Head of Data & Founder, Hexagon Bio
Millie Ray, PhD
Principal, The Column Group
Alex Kolicich
Founding Partner, 8VC
Juan Jaen, PhD
President & Co-Founder, Arcus Biosciences